Jolynn Zu Lin Ong # 1, Rui Yokomori # 1, Regina Wan Ju Wong 1, Tze King Tan 1, Ryuzo Ueda 2, Takashi Ishida 3, Shinsuke Iida 4, Takaomi Sanda 5 6 Affiliations 1Cancer Science Institute of Singapore, National University of, Singapore, 117599, Singapore. 2Department of Tumor Immunology, …
Jasmine Goh 1, Sanjay De Mel 2 3, Michal M Hoppe 1, Masturah Bte Mohd Abdul Rashid 4, Xi Yun Zhang 1, Patrick Jaynes 1, Esther Ka Yan Ng 1, Nur’Atiqa Diana Binti Rahmat 1, Jayalakshmi 1, Clementine Xin Liu 3, Limei Poon 2 3, Esther Chan 2 3, Joanne Lee 2 3, Yen Lin Chee 2 3, Liang Piu Koh 3, Lip Kun Tan 5, Teck …
Chong Yang 1, Rui Yokomori 1, Lee Hui Chua 1, Shi Hao Tan 1, Darren Qiancheng Tan 1, Kenichi Miharada 2, Takaomi Sanda 1, Toshio Suda 1 2 Affiliations 1Cancer Science Institute of Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. …
With lowering costs of sequencing and genetic profiling techniques, genetic drivers can now be detected readily in tumors but current prognostic models for Natural-killer/T cell lymphoma (NKTCL) have yet to fully leverage on them for prognosticating patients.
PINK1-Parkin mediated mitophagy, a selective form of autophagy, represents one of the most important mechanisms in mitochondrial quality control (MQC) via the clearance of damaged mitochondria.
SETDB1 is a key regulator of lineage-specific genes and endogenous retroviral elements (ERVs) through its deposition of repressive H3K9me3 mark.
According to GLOBOCAN, gastric cancer (GC) is a significant cause of cancer mortality worldwide, with over 700,000 deaths attributable to it annually. Mesenchymal-subtype gastric cancer (Mes-GC) is a particularly aggressive …
The peritoneum is a common site of metastasis in advanced gastric cancer (GC). Diagnostic laparoscopy is now routinely performed as part of disease staging, leading to an earlier diagnosis of synchronous peritoneal metastasis (PM).
Bioorthogonal catalysis (BC) generates chemical reactions not present in normal physiology for the purpose of disease treatment. Because BC catalytically produces the desired therapy only at the site of disease, it holds the promise of site-specific treatment with little or no systemic exposure or side effects.
Transcriptional reactivation of hTERT is the limiting step in tumorigenesis. While mutations in hTERT promoter present in 19% of cancers are recognized as key drivers of hTERT reactivation, mechanisms by which wildtype hTERT (WT-hTERT) promoter is reactivated, in majority of human cancers, remain unknown.
